TY - JOUR
T1 - Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission
AU - the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
AU - Díaz-Beyá, Marina
AU - Labopin, Myriam
AU - Maertens, Johan
AU - Alijurf, Mahmoud
AU - Passweg, Jakob
AU - Dietrich, Beelen
AU - Schouten, Harry
AU - Socié, Gerard
AU - Schaap, Nicolaas
AU - Schwerdtfeger, Rainer
AU - Volin, Liisa
AU - Michallet, Mauricette
AU - Polge, Emmanuelle
AU - Sierra, Jorge
AU - Mohty, Mohamad
AU - Esteve, Jordi
AU - Nagler, Arnon
N1 - Publisher Copyright:
© 2020 British Society for Haematology and John Wiley & Sons Ltd
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.
AB - Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.
KW - AML
KW - DEK-NUP214
KW - allo-SCT
KW - prognosis
KW - t(6;9) AML
UR - http://www.scopus.com/inward/record.url?scp=85078916991&partnerID=8YFLogxK
U2 - 10.1111/bjh.16433
DO - 10.1111/bjh.16433
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32020596
AN - SCOPUS:85078916991
SN - 0007-1048
VL - 189
SP - 920
EP - 925
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -
